On June 3, 2021 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") reported that three abstracts highlighting data and findings from the Company’s pivotal Phase 3 SIERRA trial for lead program Iomab-B, have been accepted for 2 oral and 2 poster presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Annual Meeting, which is being held virtually June 11 – 14, 2021 (Press release, Actinium Pharmaceuticals, JUN 3, 2021, View Source [SID1234583466]). Coinciding with SNMMI, Actinium will be hosting two Iomab-B advisory board meetings with nuclear medicine physicians, technicians, pharmacists, and physicists.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Mark Berger, Actinium’s Chief Medical Officer, commented, "We are pleased to highlight Iomab-B as well as data and findings from the pivotal Phase 3 SIERRA trial at SNMMI. Iomab-B represents a first-in-class radiotherapy for targeted conditioning given prior to a potentially curable BMT or bone marrow transplant for patients with active, relapsed or refractory acute myeloid leukemia age 55 and above. SIERRA is the only randomized Phase 3 trial to offer BMT as a treatment option to this patient population. These patients are not generally considered eligible for BMT with standard conditioning regimens, Iomab-B is also potentially best-in-class, as it has enabled all patients receiving a therapeutic dose to proceed to BMT and to engraft without delay. In addition, Iomab-B has been well tolerated with low rates of 100-day non-relapse transplant related mortality. With consistent results at 25%, 50% and 75% of target patient enrollment, we are excited to deliver results from full trial enrollment in the near future."
Iomab-B SNMMI Presentations Details:
Oral Presentation Title:
Relationship of Marrow Radiation Dose and Timing of Engraftment for Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia
Session Date:
4:00 PM – 5:00 PM ET on June 14, 2021
Session Type:
Oral – Physician Pharm
Session Title:
Cancer Radiopharmaceutical Therapy
Presenter:
Susan Passalaqua, MD, Banner MD Anderson Cancer Center
Poster Presentation Title:
Low Incidence Rates of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia with Targeted Delivery of Anti-CD45 Iodine (131I) Apamistamab [Iomab-B
Publication Number:
1694
Session Title:
Hematologic Malignancies
Presentation Time:
10:00:00 AM ET on June 14, 2021
Presenter:
Neeta Pandit-Paskar, MD, Memorial Sloan Kettering Cancer Center
Oral Presentation Title:
Feasibility of Machine Learning-Assisted Personalized Dosimetry for Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia; a Phase III Clinical trial
Session Date:
11:30 AM – 12:30 PM ET on June 14, 2021
Session Type:
Oral – Physician Pharm
Session Title:
New Tools for Optimizing Theranostic Implementation
Presenter:
Roberto Fedrigo, BC Cancer Research Institute and the University of British Columbia
Poster Presentation Title:
Feasibility of Machine Learning-Assisted Personalized Dosimetry for Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia; a Phase III Clinical trial
Publication Number:
73
Session Title:
New Tools for Optimizing Theranostic Implementation
Presentation Time:
11:30:00 AM – 12:30:00 PM ET on June 14, 2021
Sandesh Seth, Actinium’s Chairman and CEO commented, "We are honored that multiple abstracts featuring the SIERRA trial have been selected for presentation to thought leaders from around the globe at SNMMI. The nuclear medicine community is a key Iomab-B stakeholder and through its support and commitment, we have advanced to the final stages of the pivotal Phase 3 SIERRA trial. As we approach completion of the SIERRA trial, we are also excited to have the opportunity to engage with key thought leaders across multiple nuclear medicine disciplines and utilize their guidance to ensure Iomab-B’s future success. With the progress we are making, we are closer to realizing our vision of enabling better BMT outcomes and access with Iomab-B and will continue to advance towards achieving the same vision for adoptive cell and gene therapies."
About SNMMI
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.